Imidazoquinoxaline compounds and their preparation and use

Abstract

New imidazoquinoxaline compounds having the general formula ##STR1## wherein ##STR2## wherein R' is C 1-6 -alkyl, C 3-7 -cycloalkyl or C 1-6 -alkoxymethyl; and ##STR3## wherein R 5 is hydrogen or halogen. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and in improving the cognitive function of the brain of mammals.

I claim: 
     
       1. Imidazoquinoxaline compounds having the formula I ##STR16## wherein ##STR17## wherein R' is C 1-6  -alkyl, C 3-7  -cycloalkyl or C 1-6  -alkoxymethyl; and ##STR18## wherein R 5  is hydrogen or halogen. 
     
     
       2. A compound of claim 1 which is 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-isopropyl-4-oxo-imidazo[1,5-a]quinoxaline. 
     
     
       3. A pharmaceutical composition suitable for use in the treatment of a central nervous system ailment associated with the benzodiazepine receptors comprising an amount of a compound of claim 1 which is effective for the alleviation of such disorder together with a pharmaceutically-acceptable carrier or diluent. 
     
     
       4. A pharmaceutical composition according to claim 3 wherein it is in the form of an oral dosage unit containing 1-100 mg of the active compound. 
     
     
       5. A method of treating a central nervous system ailment associated with the benzodiazepine receptors in a subject in need of such treatment comprising the step of administering to said subject an amount of a compound of claim 1 which is effective for the alleviation of such ailment. 
     
     
       6. A method of treating a central nervous system ailment associated with the benzodiazepine receptors in a subject in need of such treatment comprising the step of administering to said subject an amount of a compound of claim 1 which is effective for the alleviation of such ailment in the form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically-acceptable carrier or diluent. 
     
     
       7. A compound of claim 1 which is 3-(3-cyclopropyl-1,2, 4-oxadiazol-5-yl)-4,5-dihydro-5-isopropyl-4-oxo-imidazo [1,5-a]-quinoxaline. 
     
     
       8. A compound of claim 1 which is 6-chloro-3-(5-cyclopropyl-1,2, 4-oxadiazol-5-yl)-4,5-dihydro-5-isopropyl-4-oxo-imidazo[1,5-a]-quinoxaline